Abstract:Background: Safety and efficacy of roflumilast cream 0.15% for atopic dermatitis (AD) were demonstrated in two 4-week phase 3 trials.
Objective: Evaluate long-term safety, tolerability, and efficacy of roflumilast cream 0.15% in AD.
Methods: In this open-label extension (OLE) trial (INTEGUMENT-OLE; NCT04804605), patients aged ≥6 years who completed one of the 4-week phase 3 trials applied roflumilast for up to 52 weeks. After 4 weeks of once-daily application, patients who achieved Validated Investigator Global Assessment for AD (vIGA-AD) of clear (0) switched to twice-weekly (BIW) application to normal-appearing flare-prone areas (proactive treatment).
Results: Among 657 patients treated, 36.7% reported adverse events, including 4.7% that were treatment related. Application site pain and stinging/burning that caused definite discomfort at any visit were reported for 0.5% and 0.4%–2.1% of patients, respectively. Patients who achieved vIGA-AD 0 and switched to proactive BIW application maintained vIGA-AD 0/1 (almost clear) for a median of 281 days (Kaplan–Meier estimate).
Conclusion: Roflumilast cream 0.15% was well tolerated for up to 56 weeks. BIW application to normal-appearing flare-prone sites maintained improvement in AD signs and symptoms, showing that proactive treatment represents an alternative to the current standard practice of reactive treatment.
Get full access to this article
View all access options for this article.
References
1.
SilverbergJI, GelfandJM, MargolisDJ, et al.Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018; 121(3):340–347.
2.
VakhariaPP, ChopraR, SacotteR, et al.Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol. 2017; 119(6):548–552.e3.
3.
BarbarotS, AuziereS, GadkariA, et al.Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy. 2018; 73(6):1284–1293.
4.
SilverbergJI, BarbarotS, GadkariA, et al.Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021; 126(4):417–428.e2.
5.
SilverbergJI, HanifinJM. Adult eczema prevalence and associations with asthma and other health and demographic factors: A US Population-Based Study. J Allergy Clin Immunol. 2013; 132(5):1132–1138.
6.
CapozzaK, SchwartzA. Does it work and is it safe? Parents’ perspectives on adherence to medication for atopic dermatitis. Pediatr Dermatol. 2020; 37(1):58–61.
7.
PatelNU, D’AmbraV, FeldmanSR. Increasing adherence with topical agents for atopic dermatitis. Am J Clin Dermatol. 2017; 18(3):323–332.
8.
SidburyR, TomWL, BergmanJN, et al.Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014; 71(6):1218–1233.
WangJ, BunickCG. Chemical, biochemical, and structural similarities and differences of dermatological cAMP phosphodiesterase-IV inhibitors. J Investig Dermatol. 2024; doi: 10.1016/j.jid.2024.10.597
12.
DongC, VirtucioC, ZemskaO, et al.Treatment of skin inflammation with benzoxaborole PDE inhibitors: Selectivity, cellular activity, and effect on cytokines associated with skin inflammation and skin architecture changes. J Pharmacol Exp Ther. 2016; 358(3):413–422.
13.
LebwohlMG, KircikLH, MooreAY, et al.Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: The DERMIS-1 and DERMIS-2 randomized clinical trials. JAMA. 2022; 328(11):1073–1084.
14.
KircikLH, Alonso-LlamazaresJ, BhatiaN, et al.Once-daily roflumilast foam 0.3% for scalp and body psoriasis: A randomized, double-blind, vehicle-controlled phase IIb study. Br J Dermatol. 2023; 189(4):392–399.
15.
BlauveltA, DraelosZD, Stein GoldL, et al.Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial. J Am Acad Dermatol. 2024; 90(5):986–993.
16.
ZirwasMJ, DraelosZD, DuBoisJ, et al.Efficacy of roflumilast foam, 0.3%, in patients with seborrheic dermatitis: A double-blind, vehicle-controlled phase 2a randomized clinical trial. JAMA Dermatol. 2023; 159(6):613–620.
17.
SimpsonEL, EichenfieldLF, Alonso-LlamazaresJ, et al.Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials. JAMA Dermatol. 2024; 160(11):1161–1170; doi: 10.1001/jamadermatol.2024.3121
18.
EichenfieldLF, Serrao R, PrajapatiVH, et al.Efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients aged 25 years with mild-to-moderate atopic dermatitis (INTEGUMENT-PED): A phase 3 randomized controlled trial. Pediatr Dermatol., 2025; 42(2):296–304; doi: 10.1111/pde.15840
19.
World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013; 310(20):2191–2194.
20.
JohnsonJG, HarrisES, SpitzerRL, et al.The patient health questionnaire for adolescents: Validation of an instrument for the assessment of mental disorders among adolescent primary care patients. J Adolesc Health. 2002; 30(3):196–204.
21.
KroenkeK, StrineTW, SpitzerRL, et al.The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009; 114(1–3):163–173.
22.
KovacsM. Children’s Depression Inventory (CDI and CDI 2). In: The Encylcopedia of Clinical Psychology. 1st edition.(CautinRL, LilienfeldSO, eds.) John Wiley & Sons, Inc.: Hoboken, NJ; 2015.
23.
PosnerK, BrownGK, StanleyB, et al.The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011; 168(12):1266–1277.
24.
SimpsonE, BissonnetteR, EichenfieldLF, et al.The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020; 83(3):839–846.
25.
NaegeliAN, FloodE, TuckerJ, et al.The worst itch numeric rating scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis. Int J Dermatol. 2015; 54(6):715–722.
26.
HanifinJM, ThurstonM, OmotoM, et al.The Eczema Area and Severity Index (EASI): Assessment of reliability in atopic dermatitis. Exp Dermatol. 2001; 10(1):11–18.
27.
GooderhamM, KircikL, ZirwasM, et al.The safety and efficacy of roflumilast cream 0.15% and 0.05% in patients with atopic dermatitis: Randomized, double-blind, phase 2 proof of concept study. J Drugs Dermatol. 2023; 22(2):139–147.
HixE, GustafsonCJ, O’NeillJL, et al.Adherence to a five day treatment course of topical fluocinonide 0.1% cream in atopic dermatitis. Dermatol Online J. 2013; 19:20029.
31.
TierHL, BaloghEA, BashyamAM, et al.Tolerability of and adherence to topical treatments in atopic dermatitis: A narrative review. Dermatol Ther (Heidelb). 2021; 11(2):415–431.
32.
LoA, LovellKK, GreenzaidJD, et al.Adherence to treatment in dermatology: Literature review. J Eur Acad Dermatol Venereol. 2023; 3:401–418.
33.
DraelosZD, HighamRC, OsborneDW, et al.Assessment of the vehicle for roflumilast cream compared to a ceramide-containing moisturizing cream in mild eczema. J Drugs Dermatol. 2024; 23(10):834–840.
34.
EicherL, KnopM, AszodiN, et al.A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease – strategies for optimizing treatment outcome. J Eur Acad Dermatol Venereol. 2019; 33(12):2253–2263.
35.
WollenbergA, KinbergerM, ArentsB, et al.European guideline (EuroGuiDerm) on atopic eczema - part II: Non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022; 36(11):1904–1926.
36.
LaddaM, DoironP. Addressing topical corticosteroid phobia in atopic dermatitis: The role of the pharmacist. Can Pharm J (Ott). 2021; 154(2):71–73.
37.
PavelAB, ZhouL, DiazA, et al.The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature. J Am Acad Dermatol. 2020; 82(3):690–699.
38.
BrenemanD, FleischerABJr, AbramovitsW, et al;Tacrolimus Ointment Study Group. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol. 2008; 58(6):990–999.
39.
PallerAS, EichenfieldLF, KirsnerRS, et al;US Tacrolimus Ointment Study Group. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use. Pediatrics. 2008; 122(6):e1210–e1218.
40.
SchmittJ, von KobyletzkiL, SvenssonA, et al.Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: Systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2011; 164(2):415–428.
41.
ThaciD, ChambersC, SidhuM, et al.Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: Clinical efficacy and economic impact over 12 months. J Eur Acad Dermatol Venereol. 2010; 24(9):1040–1046.
42.
BieberT. Atopic dermatitis. Ann Dermatol. 2010; 22(2):125–137.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
